Pharmaceutical Business review

Nutrition 21 full year revenues rise

Nutrition 21 has posted a net loss of $3.66m for the full year ended 30 June 2010, or $0.04 loss per diluted share, compared to a net loss of $20.81m, or $0.31 loss per diluted share, for the comparable period in 2009.

Operating income for the full year ended 30 June 2010 was $1.94m, compared to operating loss of $16,000 for the year ago period.

Nutrition 21 president and CEO Michael Zeher said that they were pleased that for the year ended 30 June 2010 their operating income was 22% of total revenues, compared to a prior year operating loss.

“Looking forward to fiscal year 2011, we anticipate that our operations will continue to improve,” Zeher said.

“We believe that delivering consistently positive EBITDA should be noted by our current shareholders as well as potential new investors.

“We look forward to developing new business opportunities both here in the US and abroad as we continue to work on achieving consistent profit and revenue growth.”